Oncology Brothers: Practice-Changing Cancer Discussions
The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients. Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format. Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice. Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities. If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com
Listen on:
Episodes
Monday Feb 26, 2024
Monday Feb 26, 2024
In discussion with Dr. Rana McKay, Associate Professor of Medicine from UC San Diego Health, we covered the treatment algorithm for Prostate cancer, starting from localized disease and then focusing on CSPC and CRPC.
#Prostate #Cancer #Cancer #2024 #oncology #oncbrothers
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
Thursday Feb 22, 2024
Thursday Feb 22, 2024
In this discussion with Dr. Hope Rugo, we covered her study Capitello-291, which led to the approval of Capivasertib in hormone receptor-positive breast cancer with AKT1, PTEN, and PIK3CA mutations, which are seen in 40-50% of the cases. We touched base on sequencing of this therapy, and important clinical pearls around the side effect management associated with this drug.
Thursday Feb 15, 2024
Thursday Feb 15, 2024
In discussion with Dr. Virginia Kaklamani, we cover treatment algorithm of HR+ breast cancer. We covered the current standard of care treatment options for HR+ breast cancer.
#HER2 #Sensitive #Breast #Cancer #2024 #oncology #oncbrothers
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
Thursday Feb 08, 2024
Thursday Feb 08, 2024
In discussion with Dr. Tian Zhang, covering the Genitourinary ASCO 2024 meeting highlights from the Community Oncology perspective. We covered 4 important practice informing studies from GU ASCO with Dr. Zhang:
- CONTACT-02: Phase 3 study of cabozantinib plus atezolizumab vs second novel hormonal therapy in patients with metastatic castration-resistant prostate cancer
- BRCAAway: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer bearing homologous recombination-repair mutations
- AMBASSADOR: Phase III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma vs observation
- Keynote-564: Overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma
Monday Feb 05, 2024
Monday Feb 05, 2024
In discussion with Dr. Harold Burstein, we cover treatment algorithm of HER2+ breast cancer. We covered the current standard of care treatment options for HER2+ breast cancer.
#HER2 #Sensitive #Breast #Cancer #2024 #oncology #oncbrothers
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
Thursday Feb 01, 2024
Thursday Feb 01, 2024
In discussion with Dr. Pamela Kunz, covering the Gastroenterology ASCO 2024 meeting highlights from Community Oncology perspective. We covered 3 important practice informing studies from GI ASCO with Dr. Kunz:
- CheckMate 8HW: Nivolumab plus ipilimumab vs chemotherapy as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer
- EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization
- NETTER-2: [177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors
Wednesday Jan 24, 2024
Wednesday Jan 24, 2024
Discussing the management using the algorithm of Triple Negative Breast Cancer (TNBC) - with Dr. Ruth O'Regan Chair of medicine Charles A. Dewey Professor at the University of Rochester Wilmot Cancer Institute & Dr. Anna Weiss Associate Professor - Department of Surgery, Oncology Wilmot Cancer Institute.
Wednesday Jan 17, 2024
Wednesday Jan 17, 2024
In discussion with Dr. Uma Borate from the Ohio State University Comprehensive Cancer Center, The James, covering the leukemia, myelofibrosis and myelodysplastic syndrome key practice changing/informing abstracts from American Society of Hematology (ASH) 2023 conference from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Borate:
- TRANSFORM-1: Ph III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, International, Study of Navitoclax in Combination with Ruxolitinib vs Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis
- MANIFEST-2: Ph III, Randomized, Double-Blind Study, Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis
- SAVE: Phase I/II, Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax in AML
- AUGMENT-101: Ph I/II, Revumenib Monotherapy in Patients with R/R KMT2Ar Acute Leukemias: Efficacy and Safety Results
#ASH #Leukemia #MDS #Myelofibrosis #Blood #Cancer #2023 #oncology #oncbrothers
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
Thursday Jan 11, 2024
Thursday Jan 11, 2024
In discussion with Dr. Daniel G. Stover, covering the San Antonio Breast Cancer Symposium 2023 Highlights from Community Oncology perspective. We covered 3 important practice informing studies in HER2+ disease with Dr. Stover:
- APHINITY Sub-analysis: Benefit of Adj Pertuzumab and Trastuzumab According to ER and HER2 Expression
- KATHERINE Update: Phase III Study of Adjuvant TDM-1 vs Trastuzumab for Residual Invasive HER2-positive Early Breast Cancer After Neoadj Chemo: Final IDFS and Updated OS analysis
- HER2CLIMB-02: Randomized, Double-blind Phase 3 Trial of Tucatinib and TDM1 for Previously Treated HER2-positive Metastatic Breast Cancer
Monday Jan 08, 2024
Monday Jan 08, 2024
In discussion with Dr. Hope Rugo, covering the San Antonio Breast Cancer Symposium 2023 Highlights from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Rugo:
- NATALEE Update – Ribociclib + Nonsteroidal AI as Adj Treatment in Patients with HR+/HER2− Early Breast Cancer: Final iDFS analysis
- MONARCH 3 – Final OS Results of Abemaciclib Plus a Nonsteroidal AI as First-line Therapy for HR+, HER2– Advanced Breast Cancer
- INAVO120 – Phase III Study of Inavolisib or Placebo in Combination with Palbociclib and Fulvestrant in Patients with PIK3CA-mut, HR+, HER2– Locally Adv/Metastatic Breast Cancer
- TROPION-Breast01 – Phase III Study of Dato-DXd vs Chemo for Patients with Previously Treated Inoperable/Metastatic HR+, HER2– Breast Cancer